← Eichor
Condition: Her2 Low Expressing Breast Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Her2 Low Expressing Breast Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
Phase 1/Phase 2 · 11 location(s) · Vironexis Biotherapeutics Inc. · NCT07192432Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 N
Phase 2 · 13 location(s) · TransThera Sciences (Nanjing), Inc. · NCT07498478Real-world Study of Trastuzumab Deruxtecan in Patients With Unresectable or Metastatic HER2-low Breast Cancer
Phase N/A · 14 location(s) · AstraZeneca · NCT06727227Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Canc
Phase 2 · 1 location(s) · RemeGen Co., Ltd. · NCT06642545TRUDI: TDXD+Durva in HER2+/Low IBC
Phase 2 · 3 location(s) · Filipa Lynce, MD · NCT05795101Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
EARLY_Phase 1 · 1 location(s) · Vanderbilt-Ingram Cancer Center · NCT06828588Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer
Phase 2 · 1 location(s) · Yonsei University · NCT06837792HER2-PET Imaging in HER2-low Breast Cancers
Phase 1/Phase 2 · 1 location(s) · Centre de recherche du Centre hospitalier universitaire de S · NCT06732336Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer
Phase N/A · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT07358182DESTINY Breast Respond HER2-(Ultra)Low Europe
Phase N/A · 211 location(s) · Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · NCT05945732Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)
Phase 3 · 3 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT05904964Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast C
Phase 2 · 5 location(s) · RemeGen Co., Ltd. · NCT06227117Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for H
Phase 1 · 2 location(s) · National Cancer Institute (NCI) · NCT07137416A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC
Phase 2 · 1 location(s) · MediLink Therapeutics (Suzhou) Co., Ltd. · NCT06439771HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBC
Phase N/A · 1 location(s) · Renske Altena · NCT06830382Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressin
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT06877416To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvan
Phase 2 · 1 location(s) · RemeGen Co., Ltd. · NCT06389006A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer
Phase 2 · 1 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT07497386
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.